Health Catalyst Announces ~$5 Million Stock Repurchase
Rhea-AI Summary
Health Catalyst (HCAT) has announced a stock repurchase of approximately $5 million, executed between March 3-10, 2025. The company retired approximately 1.1 million shares of common stock as part of its existing share repurchase program, which was authorized in August 2022 with a total capacity of $40 million.
CEO Dan Burton stated that the repurchase reflects the company's confidence in its future, citing that current market prices don't reflect their long-term value. The company anticipates continued achievement of operating leverage and revenue growth reacceleration, emphasizing their commitment to creating sustainable value for shareholders, clients, and team members.
Positive
- Repurchased and retired 1.1 million shares, reducing share count and potentially improving EPS
- Management confidence in company's future demonstrated through $5M buyback
- Anticipates continued operating leverage improvement
- Expects revenue growth reacceleration
Negative
- Only $5M of the $40M authorized buyback program utilized since August 2022
- Current market valuation deemed unfavorable by management
News Market Reaction – HCAT
On the day this news was published, HCAT gained 5.04%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
These repurchased shares were acquired between March 3, 2025, and March 10, 2025, as part of Health Catalyst's existing share repurchase program approved by its board of directors on August 2, 2022, which authorized repurchases of up to
"Our repurchase of shares underscores our confidence in the future of our business," said Dan Burton, CEO of Health Catalyst. "We believe the current market does not reflect the long-term value of our shares of common stock, including our anticipated continued achievement of operating leverage and our reacceleration of revenue growth. This repurchase demonstrates our continued commitment to creating long-term, sustainable value for our shareholders, our clients, and our team members."
About Health Catalyst
Health Catalyst (Nasdaq: HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,000 organizations worldwide rely on Health Catalyst's offerings, including our cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to Health Catalyst's operating leverage, revenue growth and stock performance. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Health Catalyst's future performance and opportunities. These forward-looking statements represent Health Catalyst's expectations as of the date of this press release, and involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in the forward-looking statements as a result of numerous factors, many of which are beyond Health Catalyst's control. Important risks and uncertainties that could cause Health Catalyst's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to Health Catalyst's business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to Health Catalyst's technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners; (v) macroeconomic challenges (including high inflationary and/or high interest rate environments, or market volatility caused by bank failures and measures taken in response thereto) and any new public health crisis; and (vi) changes to Health Catalyst's abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect Health Catalyst's actual results, please refer to the risk factors identified in Health Catalyst's SEC reports, including, but not limited to the Annual Report on Form 10-K for the year ended December 31, 2024 filed on February 26, 2025, available at www.sec.gov. While Health Catalyst may elect to update such forward-looking statements at some point in the future, Health Catalyst disclaims any obligation to do so, even if subsequent events cause Health Catalyst's views to change.
Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855)-309-6800
ir@healthcatalyst.com
Media Contact:
Kathryn Mykleseth
PR and Communications Director
media@healthcatalyst.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/health-catalyst-announces-5-million-stock-repurchase-302397725.html
SOURCE Health Catalyst
FAQ
How many shares did Health Catalyst (HCAT) repurchase in March 2025?
What is the total size of Health Catalyst's (HCAT) share repurchase program?
How much did Health Catalyst (HCAT) spend on its March 2025 stock buyback?
What is the strategic reason behind Health Catalyst's (HCAT) stock buyback?
